Higinio T. Mappala
Non-alcoholic fatty liver disease (NAFLD) is one of the most
common forms of chronic liver disease which may progress to
non-alcoholic steatohepatitis (NASH). Currently there are no
therapeutic strategies for such disease. Only lifestyle modification
through diet and exercise were proven to afford some benefit
in patients with NAFLD. No pharmacologic agents have
so far been approved for the treatment of NAFLD or NASH.
Therefore, most clinical efforts have been directed at treating
the components of metabolic syndrome, namely obesity, diabetes,
hypertension and dyslipedemias. Other interventions are
directed at specific pathways potentially involved in the pathogenesis
of NAFLD, such as insulin resistance, oxidative stress,
proinflammatory cytokines, apoptosis, bacterial overgrowth,
and angiotensin pathway.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu